The Research and Development Center for Medicinal Plants and Plant Drugs

Xiamen, China

The Research and Development Center for Medicinal Plants and Plant Drugs

Xiamen, China
SEARCH FILTERS
Time filter
Source Type

Ming Y.,The Research and Development Center for Medicinal Plants and Plant Drugs | Zheng Z.,The Research and Development Center for Medicinal Plants and Plant Drugs | Chen L.,The Research and Development Center for Medicinal Plants and Plant Drugs | Zheng G.,The Research and Development Center for Medicinal Plants and Plant Drugs | And 3 more authors.
Cell Biology International | Year: 2013

Hepatocellular carcinoma (HCC) is one of most common types of malignant tumours. Therefore, it is very important to identify powerful drugs and their antitumour mechanisms. Corilagin has a significant antitumour potential and lower toxicity in normal cells in vitro. The IC50 values of corilagin for normal Chang-liver cells and the HCC cell lines Bel7402 and SMMC7721 were 131.4, 24.5 and 23.4 mM, respectively, in the methyl thiazolyl tetrazolium (MTT) assay. MHCC97-H xenografts in Balb/c mice intraperitoneally injected with 30 mg/kg corilagin for 5 weeks showed a 47.3% inhibition of tumour growth in vivo. Furthermore, data from flow cytometry and Western blot analyses of cell cycle and cell cycle-related proteins suggest that corilagin arrests SMMC7721 cells at the G2/M phase by downregulating p-Akt and cyclin B1/cdc2 and upregulating p-p53 and p21Cip1. In conclusion, corilagin is a potential antitumour drug that is effective in retarding the growth of HCC, which is correlated with the activation of p-p53-p21Cip1-cdc2/cyclin B1. © 2013 International Federation for Cell Biology.

Loading The Research and Development Center for Medicinal Plants and Plant Drugs collaborators
Loading The Research and Development Center for Medicinal Plants and Plant Drugs collaborators